Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
South Korea Business Strategies Commercial

Dong-A ST Faces New Wave Of Change As It Challenges Norms

Park Looks To Shake Up 'Outdated' R&D Approaches

  • Interviews

Executive Summary

Dong-A ST’s president of R&D Jae-Hong Park talks to Scrip about the changes needed in the domestic pharma sector and wider industry if Korean biopharma firms are to step up to global levels.

You may also be interested in...



Dong-A ST Achieves Therapeutic Equivalence With Stelara Biosimilar

Dong-A has achieved therapeutic equivalence for its ustekinumab biosimilar candidate DMB-3115 in clinical studies and now plans to file for marketing authorization for the product in both the EU and US.

Asia Deal Watch: Dong-A Brings In NeuroBo As Partner On Pair Of Cardiometabolic Candidates

Plus deals involving Takeda/Puma, SillaJen/Basilea, Celltrion/Abpro, METiS/Voronoi, Yuhan/AtoGen, Biocytogen/FineImmune and Avance/C3.

Celltrion Eyes M&A, Global Expansion And Novel Drugs As Founder Returns

Celltrion founder and chairman Jung Jin Seo has outlined why he has decided to return to the Korean biosimilars major and the business priorities for the group if it is to emerge as a top-tier global biopharma operation.

Table

View full table

Topics

Related Companies

Tags:
South Korea Business Strategies Commercial
Latest Headlines

First Drugs That Could Be Picked For Price Negotiation Showcase Longevity Of Some Brands

ThirtyFiveBio Makes Its Debut With First-In-Class GPR35 Antagonist Approach

Investors Take Flight After Bluebird Bio’s Sickle Cell Delay

Roche Continues To Cast Its Collaborations Net Wide

See All
UsernamePublicRestriction

Register

SC148059

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By